BHUBANESWAR: In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) ...

In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) has approved ...

Agios Pharmaceuticals has reported full-year 2025 results, with revenue rising to US$54.03 million from US$36.50 million a year earlier, while swinging from net income of US$673.73 million to a net ...

Agios Pharmaceuticals AGIO reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks ...

Study reveals that reversible chemical modifications can inhibit pyruvate kinase and affect its variants differently, ...

Pyruvate kinase (PK) catalyzes the last step in glycolysis, the pathway by which glucose is metabolized. In humans, the M1 isoform of PK (PKM1) is constitutively active, but the activity of the highly ...

Non-small-cell lung cancer (NSCLC) accounts for up to 85% of all cases of lung cancer, which is the most frequent cause of cancer-related deaths worldwide. The need for effective treatments against ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...

Introduction:: Pyruvate kinase M2 (PKM2), the rate-limiting enzyme of glycolysis, plays a critical role in macrophage activation and a broad spectrum of chronic liver diseases. However, whether PKM2 ...